• Fri news: New Novo obesity prospect linked to psychiatric side effects. Summit beats Keytruda in NSCLC. DermaSensor skin cancer detection device. Astellas digital health product. Sanofi MS data. See more on our front page

BMS chases Merck/Seagen with first-line bladder cancer filing

Quote
cafead

cafead

Administrator
Staff member
  • cafead   Dec 06, 2023 at 12:02: AM
via The FDA has started a priority review of Bristol-Myers Squibb Opdivo in combination with cisplatin as a first-line therapy for advanced urothelial carcinoma (UC), setting an action date of 5th April next year for a decision.

article source
 

<



Similar threads

cafead
FDA weighs limiting PD-1 drugs in stomach cancer, calls on experts to discuss Merck, BMS and BeiGene meds
Replies
0
Views
32
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BMS eyes April FDA verdict on Opdivo/Yervoy in liver cancer
Replies
0
Views
9
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BMS’ KarXT nears schizophrenia approval, but AbbVie and others wait in the wings
Replies
0
Views
44
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BMS ditches TIGIT, walking away from $200M bet on Agenus bispecific
Replies
0
Views
15
Pharma/Biotech Companies - In the News
cafead
cafead
cafead
BMS Gets Q2 Beat, Raises Full-Year Guidance as Cost-Cutting Initiative Continues
Replies
0
Views
27
Pharma/Biotech Companies - In the News
cafead
cafead
Top Bottom
Back
Quote